Our results support the critical concept that the intrinsic differences in cellular redox status, the RelB-BLNK axis, and the different adaptive responses to prooxidants by normal cells and cancer cells can be used to identify drugs that would protect against normal tissue injury while increasing RT efficacy. This evidence concerns the gene RELB and cancer.